ArticleJNCI cancer spectrum2026
Pandemic-era increases in late-stage pediatric cancer diagnoses, 2020-2022.
Article in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
COVID-19 pandemic-related disruptions may have altered pediatric cancer detection in the United States. Using the National Childhood Cancer Registry, we compared observed incidence rates among individuals aged 0-17 years during 2020-2022 with expected rates with 95% credible intervals (CrIs) derived from pre-pandemic trends. Rates were evaluated overall and by race/ethnicity, cancer site, and stage-at-diagnosis. Among 27 996 cancers diagnosed in 2020-2022, total incidence was 17.44 per 100 000, similar to the expected rate of 17.39 (95% CrI = 16.80-17.98). Annual patterns showed an incidence reduction in 2020, followed by modestly higher-than-expected rates in 2021-2022. Pandemic-era late-stage incidence was significantly higher than expected, however (10.58 vs 10.19 per 100 000). Overall, pediatric cancer incidence during the COVID-19 pandemic matched expectations, but late-stage diagnoses increased, underscoring the need to restore timely evaluation and maintain diagnostic access during health-system disruptions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.